HER2 positive breast cancer
Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
... of HER2-positive breast cancer patients treated with neoadjuvant chemotherapy associated with ...in breast and axilla) was not a statistically significant prognostic factor in our ...the ...
6
Inherited predisposition of early-onset HER2-positive breast cancer
... Early-onset HER2-positive Breast Cancer Since the initial description of the Li-Fraumeni syndrome, several criteria have been suggested to identify high-risk families (McCuaig et ...with ...
102
Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report
... Trastuzumab emtansina (T-DM1) is an antibody-drug conju- gate directed against the HER2 for the treatment of HER2+ mestastatic breast cancer (MBC), who has previously received trastuzumab ...
5
Identification of HER2-positive breast cancer patients with a high risk of developing brain metastases: A Portuguese single-center retrospective analysis
... mama HER2+ [16] ...NMM HER2+ têm sintomas quando do diagnóstico de MC, o que contrasta com 39% mencionado num outro estudo [18] ...NMM HER2+ e a maioria deles teve mais de 3 metástases (69%), à ...
46
For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
... for HER2-positive breast cancer [12– ...Comprehensive Cancer Network H (NCCN) Clinical Practice Guidelines in Oncology for Breast Cancer [17] as well as the ...Early ...
7
Breast cancer HER2-positive: sequential versus concomitant therapy
... At the end of this study, to our knowledge, this is one of the major studies trying to compare the concomitant and sequential therapy used in HER2-positive breast cancer. The comparison of ...
52
Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies
... of HER2-positive breast cancer over the last few ...response. HER2/HER3 dimerization is required for full signaling potential and constitutes the key oncogenic ...treat ...
39
Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
... Finally, we attempted to verify the accuracy of using the 20% threshold to define PgR posi- tivity. None of the variables markedly differed between patients with ER+/PgR purely negative/ HER2- tumours and ...
12
Targeted therapies for triple-negative breast cancer
... the HER2, 105 chronic stimulation by cytokines 106 and other forms of intense mitogenic ...a positive upstream regulator of p-RB, and both are cyclin-dependent kinase inhibitors that work as strong negative ...
89
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
... EGFR positive, and the fact that some patients had CTCs that were HER2 ...with HER2 non-amplified tumors however (progression in all patients within 12 weeks) including 3 out of 14 (21%) patients who ...
7
Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.
... primary breast cancer ...of positive axillary nodes was not known, we used a slightly different defini- tion for the NPI, as described by Teschendorff et al [36]: NPI = ...be positive (1) or ...
12
Metaplastic Breast Cancer and EGFR Expression
... Metaplastic breast cancer has poor prognosis and is usually triple nega- ...negative breast cancers, expression proile is more ...metaplastic breast cancer cases regarding their pathol- ...
4
Breast cancer in pregnancy: case report
... right breast mass that was firm and non-tender measuring ...by breast ultrasound, a breast mass highly suspicious for breast malignancy was ...right breast incisional biopsy (under ...
6
Targeted therapies in breast cancer
... However, an interesting study design a conjugate that can distinguish high HER2 expression levels from low levels (113). This study, aims to target STAT3 (signal transducer and activators of transcription 3), ...
52
Weakly-supervised classification of HER2 expression in breast cancer haematoxylin and eosin stained slides
... not positive for HER2, there are no morphological features on H&E slides that allow a reliable prediction of the HER2 ...the HER2 status could be extracted only from H&E whole slide ...
11
Biological effects of phytocannabinoids and endocannabinoids on oestrogen receptor-positive (ER+) breast cancer cells
... as HER2, epidermal growth factor receptor (EGFR), fibroblast growth factor receptor 1 (FGFR1) and insulin-like growth factor 1 receptor (IGF1R), as well as G-protein coupled receptors (GPR30) (7), leading to ...
90
Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients.
... characteristics Her2 receptor was expressed in the primary tumors of 18 patients, while the rest had either no protein expression or gene amplification in ...had positive lymph nodes, but with no detectable ...
8
Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ + and HER2– – locally advanced breast cancer
... The HER2+ + cohort consisted mainly of advanced BC stages at diagnosis, high-grade pathological classification, and lack of hormone receptor ...receptor positive patients ...the HER2+ + population, ...
7
Exploring epigenetic profiling as prognostic/predictive markers of endocrine resistance in estrogen receptor positive breast cancer
... annual breast ultra-sound and mammogram plus annual bone scintigraphy plus annual CT scan), and conversely, high expression being associated to better prognosis, a standard protocol (clinical visits according to ...
130
Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX
... Jeong developed an RNA aptamer against HER protein, and proposed that the selected aptamer could potentially be utilized as imaging agents for HER ‐ positive cancers . Giangrande et al used cell‐ internalization ...
11